88 related articles for article (PubMed ID: 3690545)
1. Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; Angel C; Berman M
Cancer Treat Rep; 1987 Dec; 71(12):1303-4. PubMed ID: 3690545
[No Abstract] [Full Text] [Related]
2. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Thigpen T; Blessing JA; Yordan E; Valea F; Vaccarello L
Gynecol Oncol; 1996 Oct; 63(1):120-2. PubMed ID: 8898180
[TBL] [Abstract][Full Text] [Related]
3. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
Rose PG; Blessing JA; Soper JT; Barter JF
Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; DiSaia PJ; Christopherson WA
Cancer Treat Rep; 1987 Jun; 71(6):661-2. PubMed ID: 3034423
[No Abstract] [Full Text] [Related]
5. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; Delgado G
Cancer Treat Rep; 1982 Aug; 66(8):1669-71. PubMed ID: 7105059
[No Abstract] [Full Text] [Related]
6. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Sutton G; Blessing J; Hanjani P; Kramer P;
Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study.
Sutton G; Blessing JA; Ball H
Gynecol Oncol; 1999 Sep; 74(3):346-9. PubMed ID: 10479491
[TBL] [Abstract][Full Text] [Related]
8. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.
Smith HO; Blessing JA; Vaccarello L
Gynecol Oncol; 2002 Jan; 84(1):140-4. PubMed ID: 11748990
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Slayton RE; Blessing JA; Homesley HD
Cancer Treat Rep; 1984 Dec; 68(12):1513-4. PubMed ID: 6509456
[No Abstract] [Full Text] [Related]
10. Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study.
Long HJ; Blessing JA; Sorosky J
Gynecol Oncol; 2005 Nov; 99(2):339-42. PubMed ID: 16051328
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of etoposide in the management of advanced or recurrent squamous cell carcinoma of the vulva and carcinoma of the vagina: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; Beecham J; DiSaia PJ
Cancer Treat Rep; 1987 Sep; 71(9):869-70. PubMed ID: 3621221
[No Abstract] [Full Text] [Related]
13. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.
Sutton G; Blessing JA; Malfetano JH
Gynecol Oncol; 1996 Aug; 62(2):226-9. PubMed ID: 8751554
[TBL] [Abstract][Full Text] [Related]
14. Prolonged oral etoposide for refractory advanced uterine leiomyosarcoma.
Chantarawiroj P; Tresukosol D; Kudelka AP; Edwards CL; Silva EG; Wharton JT; Kavanagh JJ
Gynecol Oncol; 1995 Aug; 58(2):248-50. PubMed ID: 7622113
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study.
Currie J; Blessing JA; Muss HB; Fowler J; Berman M; Burke TW
Gynecol Oncol; 1996 Apr; 61(1):27-30. PubMed ID: 8626112
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group.
Thigpen JT; Blessing JA; Wilbanks GD
Am J Clin Oncol; 1986 Feb; 9(1):18-20. PubMed ID: 3953489
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
Currie JL; Blessing JA; McGehee R; Soper JT; Berman M
Gynecol Oncol; 1996 Apr; 61(1):94-6. PubMed ID: 8626125
[TBL] [Abstract][Full Text] [Related]
18. A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus. A Gynecologic Oncology Group study.
Slayton RE; Blessing JA; Look K; Anderson B
Invest New Drugs; 1991 May; 9(2):207-8. PubMed ID: 1874603
[TBL] [Abstract][Full Text] [Related]
19. Prolonged oral etoposide for advanced uterine leiomyosarcoma with pulmonary metastases: case report.
Termrungruanglert W; Kudelka AP; Piamsomboon S; Edwards CL; Tornos C; Kavanagh JJ
Eur J Gynaecol Oncol; 1997; 18(2):97-100. PubMed ID: 9105854
[TBL] [Abstract][Full Text] [Related]
20. Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study.
Asbury R; Blessing JA; Buller R; Malfetano JH; Walker J; Sevin BU
Am J Clin Oncol; 1998 Apr; 21(2):145-6. PubMed ID: 9537200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
